Aligos Therapeutics (ALGS) to Release Earnings on Monday

Aligos Therapeutics (NASDAQ:ALGS) is anticipated to release its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Aligos Therapeutics to post earnings of ($2.09) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

Aligos Therapeutics Stock Performance

Shares of Aligos Therapeutics stock opened at $7.03 on Monday. Aligos Therapeutics has a 1 year low of $3.76 and a 1 year high of $17.39. The firm’s 50-day simple moving average is $8.23 and its 200-day simple moving average is $9.13. The firm has a market cap of $43.23 million, a PE ratio of -0.36 and a beta of 2.67.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently made changes to their positions in ALGS. Susquehanna International Group LLP acquired a new position in Aligos Therapeutics during the 3rd quarter valued at approximately $99,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter worth $106,000. DRW Securities LLC bought a new stake in Aligos Therapeutics in the fourth quarter valued at $111,000. XTX Topco Ltd bought a new stake in Aligos Therapeutics in the second quarter valued at $100,000. Finally, Jane Street Group LLC acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at $226,000. Institutional investors own 60.43% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Aligos Therapeutics has an average rating of “Hold” and a consensus target price of $35.00.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.